Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Common and rare variants in SLCO1B1 are associated with statin intolerance

View ORCID ProfileMargherita Bigossi, View ORCID ProfileCyrielle Maroteau, View ORCID ProfileAdem Y Dawed, View ORCID ProfileAlasdair Taylor, View ORCID ProfileSundararajan Srinivasan, View ORCID ProfileAlaa’ Lufti Melhem, View ORCID ProfileEwan R Pearson, View ORCID ProfileRoberto Pola, View ORCID ProfileColin N A Palmer, View ORCID ProfileMoneeza K Siddiqui
doi: https://doi.org/10.1101/2022.08.09.22278584
Margherita Bigossi
1Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee DD1 9SY
2Section of Internal Medicine and Thromboembolic Diseases, Department of Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Margherita Bigossi
Cyrielle Maroteau
1Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee DD1 9SY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cyrielle Maroteau
Adem Y Dawed
1Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee DD1 9SY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adem Y Dawed
Alasdair Taylor
1Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee DD1 9SY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alasdair Taylor
Sundararajan Srinivasan
1Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee DD1 9SY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sundararajan Srinivasan
Alaa’ Lufti Melhem
1Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee DD1 9SY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alaa’ Lufti Melhem
Ewan R Pearson
1Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee DD1 9SY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ewan R Pearson
Roberto Pola
2Section of Internal Medicine and Thromboembolic Diseases, Department of Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roberto Pola
Colin N A Palmer
1Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee DD1 9SY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Colin N A Palmer
Moneeza K Siddiqui
1Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee DD1 9SY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Moneeza K Siddiqui
  • For correspondence: m.k.siddiqui@dundee.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background and Aims The efficacy of statin therapy is hindered by adverse drug reactions, most frequently musculoskeletal symptoms. Variants in SLCO1B1, which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentration of the drug and its metabolites. While pharmacogenetic testing of the loss-of-function Val174Ala (rs4149056T>C) is recommended to reduce risk of statin intolerance, current guidelines acknowledge the potential role of gain-of-function variants. This study tests the hypothesis that accounting for gain-of-function variants in SLCO1B1, in addition to Val174Ala, will provide more reliable estimates of statin intolerance.

Methods and Results High-risk haplotypes were derived from Val174Ala and three common gain-of-function SLCO1B1 variants and compared to low-risk haplotypes. In statin users from Tayside Scotland, UK, those with high-risk haplotypes had increased odds across three phenotypes of statin intolerance (general statin intolerance: ORGSI 2.42[95%CI:1.29, 4.31], p=0.003; statin-related myopathy ORSRM 2.51[95%CI:1.28, 4.53],p=0.004; statin-related suspected rhabdomyolysis: ORSRSR 2.85[95%CI:1.03, 6.65],p=0.02). In contrast, using the Val174Ala genotype alone produced weaker results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (ORVal174Ala 1.99 [95%CI:1.01, 3.95],p=0.048; ORrisk-haplotypes 1.76 [95%CI:1.16, 2.69],p=0.008). For those requiring high-dose statin therapy, high-risk haplotypes were more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared to Val174Ala (general statin intolerance: HRVal174Ala 2.49 [95%CI:1.09, 5.68],p=0.03; HRrisk-haplotypes 2.44 [95%CI:1.46, 4.08],p<0.001). Exome-sequenced rare variants were found to be associated with the risk of intolerance (p=0.02).

Conclusions We demonstrate that accounting for gain-of-function variants in SLCO1B1, in addition to Val174Ala, provides more reliable estimates of statin intolerance.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was partly funded by the National Institute for Health Research (NIHR) (INSPIRED 16/136/102) using aid from the UK government to support global health research. GoDARTS was funded and supported by the Wellcome Trust (Award 072960 and 084726) and the UK Medical Research Council (Award G0601261). SHARE is NHS Scotland Research (NRS) infrastructure initiative and it was funded by the Chief Scientists Office of the Scottish Government. Additional Funding and initiation of the spare blood retention at NHS Tayside was supported by the Wellcome Trust Biomedical Resource (award number 099177/Z/12/Z). PREDICTION-ADR has received funding form the European Community's Seventh Framework Programme (FP7/2007-2013) under Grant Agreement no. 602108. The UK Biobank was primarily funded by the Wellcome Trust and the Medical Research Council. Approval for the study and permission to access the data was granted by the UK Biobank Resource under Application Number 20405.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

GoDARTS and SHARE studies were reviewed and approved by Tayside Medical Ethics Committee 053/04 and East of Scotland Ethics committee NHS REC 13/ES/0020. Multiple EU Research Ethics Committees (Tayside, Scotland; North West England, UK: Sefton, UK) gave ethical approval for the PREDICTION-ADR study. UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval, REC reference: 21/NW/0157, IRAS project ID: 299116.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

GoDARTS and SHARE data are available subject to approval by the Tayside data access committee and can be made by contacting the corresponding authors. PREDICTION-ADR data are available subject to approval and can be made by contacting the corresponding authors. UK Biobank data are available via application directly to the UK Biobank, https://www.ukbiobank.ac.uk

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 10, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Common and rare variants in SLCO1B1 are associated with statin intolerance
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Common and rare variants in SLCO1B1 are associated with statin intolerance
Margherita Bigossi, Cyrielle Maroteau, Adem Y Dawed, Alasdair Taylor, Sundararajan Srinivasan, Alaa’ Lufti Melhem, Ewan R Pearson, Roberto Pola, Colin N A Palmer, Moneeza K Siddiqui
medRxiv 2022.08.09.22278584; doi: https://doi.org/10.1101/2022.08.09.22278584
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Common and rare variants in SLCO1B1 are associated with statin intolerance
Margherita Bigossi, Cyrielle Maroteau, Adem Y Dawed, Alasdair Taylor, Sundararajan Srinivasan, Alaa’ Lufti Melhem, Ewan R Pearson, Roberto Pola, Colin N A Palmer, Moneeza K Siddiqui
medRxiv 2022.08.09.22278584; doi: https://doi.org/10.1101/2022.08.09.22278584

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (558)
  • Anesthesia (135)
  • Cardiovascular Medicine (1771)
  • Dentistry and Oral Medicine (239)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10816)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2961)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1934)
  • Health Policy (836)
  • Health Systems and Quality Improvement (746)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12528)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (88)
  • Nephrology (325)
  • Neurology (2811)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (599)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (869)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (339)
  • Psychiatry and Clinical Psychology (2649)
  • Public and Global Health (5384)
  • Radiology and Imaging (1018)
  • Rehabilitation Medicine and Physical Therapy (598)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)